Press Latest Release http://www.csl.com.au CSL News Mon, 10 Jul 2017 00:00:00 -0500 CSL Response to Patent Infringement Complaint thumbnail CSL Limited has become aware that Bioverativ has filed complaints in the U.S. District Court for the District of Delaware and with the International Trade Commission. http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252905315629/prdetail.htm 1252905315629 Fri, 23 Jun 2017 00:00:00 -0500 HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) FDA Approval thumbnail CSL today announced that the U.S. Food and Drug Administration (FDA) has approved CSL Behring’s HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), the only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252905126372/prdetail.htm 1252905126372 Tue, 13 Jun 2017 00:00:00 -0500 CSL to acquire majority stake in Chinese plasma fractionatorWuhan Zhong Yuan Rui De Biologicals Products thumbnail CSL to acquire an 80 per cent stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biologics (“Ruide”) in China for US$352 million.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252904953475/prdetail.htm 1252904953475 Thu, 01 Jun 2017 00:00:00 -0500 Applications Open for CSL Centenary Fellowship Program$1.25 Million Funding Available to Australia’s Best and Brightest Biomedical Researchers thumbnail Australia’s biomedical researchers are invited to apply for one of two CSL Centenary Fellowships each worth $1.25million over five years in support of discovery and translational medical research.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252904808110/prdetail.htm 1252904808110 Wed, 12 Apr 2017 00:00:00 -0500 CSL Response to Patent Complaint thumbnail CSL remains highly confident that CSL830 does not infringe any valid claim of the Shire ViroPharma patent and will vigorously defend against the claims.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252904542423/prdetail.htm 1252904542423 Wed, 15 Feb 2017 00:00:00 -0500 Half Year Result 20171 thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $806 million for the six months ended 31 December 2016, up $87 million or 12% on a reported basis when compared to the prior comparable period (PCP).   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252904041419/prdetail.htm 1252904041419 Fri, 10 Feb 2017 00:00:00 -0500 Study Published in Cell Metabolism shows Potential New Therapy for Diabetic Kidney Disease thumbnail Melbourne, 10 February, 2017 04.00AM AEDT: An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the progression of Diabetic Kidney Disease (DKD) in laboratory studies of type 2 diabetes.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252904056688/prdetail.htm 1252904056688 Thu, 19 Jan 2017 09:00:00 -0500 FY2017 profit upgrade thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) today upgraded its net profit after tax (NPAT) expectation for FY2017. Following strong sales performance, CSL expects to report NPAT of approximately US$800 million for the six months ended 31 December 2016.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252903872987/prdetail.htm 1252903872987 Thu, 05 Jan 2017 00:00:00 -0500 Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors thumbnail Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that they have entered into an exclusive research collaboration and worldwide license agreement to develop and commercialize Fc multimer proteins, including Momenta’s M230, a selective immunomodulator of Fc receptors, which is expected to enter the clinic in 2017.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252903829512/prdetail.htm 1252903829512